Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
AAO 2025: Understanding and diagnosing endophthalmitis | Ophthalmology Times
Note: Video captions are generated with the assistance of AI and may contain errors. At the 2025 annual meeting of the American Academy of Ophthalmology, Sunir J. Garg, MD, gave a presentation titled, “Endophthalmitis Sterile or not.” In an interview…
AAO 2025: Diana Do, MD, reviews the real-world use of aflibercept 8 mg | Ophthalmology Times
Note: Video captions are generated with the assistance of AI and may contain errors. Diana Do, MD, a professor of ophthalmology and vice chair of Clinical Affairs at Stanford University’s Byers Eye Institute, presented research on aflibercept 8 mg in…
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial | Ophthalmology Times
(Image Credit: AdobeStock/tonstock) Aurion Biotech has released positive 12-month results from its phase 1/2 CLARA trial evaluating the safety, efficacy, and tolerability of AURN001 in patients with corneal edema secondary to corneal endothelial dysfunction. In the CLARA trial, a double-masked,…
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus | Ophthalmology Times
Glaukos’ FDA-approved Epioxa topical therapy offers a first-of-its-kind, incision-free treatment for patients with keratoconus, according to the company. Glaukos announced that the FDA has approved the new drug application for its topical drug therapy (Epioxa HD/Epioxa) for keratoconus.1,2 This approval…
Breaking down the barriers: Ophthalmic care in the incarcerated population | Ophthalmology Times
(Image Credit: AdobeStock/methaphum) The US has the highest incarcerated population globally, with Black, Indigenous, or Hispanic individuals significantly more likely to be imprisoned than White individuals. These racial disparities mirror those seen in vision health and access to eye care.1,2…
AAO 2025: Glaucoma laser surgery with Joel S. Schuman, MD, FACS | Ophthalmology Times
Joel S. Schuman, MD, FACS, of Wills Eye Hospital, presented an update on laser therapies for glaucoma, emphasizing recent innovations in selective laser trabeculoplasty (SLT) and laser cyclophotocoagulation at the American Academy of Ophthalmology 2025 annual meeting, October 18 to…
Q&A: The ARCHER trial and the importance of continued GA research | Ophthalmology Times
(Image credit: AdobeStock/J Bettencourt) In conversation with Sydney M. Crago, Managing Editor of Ophthalmology Times, David R. Lally, MD, spoke about his presentation at the 2025 Retina Society meeting, which highlighted the results from the ARCHER trial (NCT04656561) of ANX007…
Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial | Ophthalmology Times
Image credit: AdobeStock/MrAshi On September 4, 2025, Merck and EyeBio announced that the companies have initiated the Phase 2b/3 BRUNELLO trial (NCT06571045) to evaluate the candidate MK-3000, formerly known as EYE103 for the treatment of patients with diabetic macular edema…
Heterogeneous Ocular Biomarkers May Predict Sjögren’s Disease Extraocular Features | Ophthalmology Times
(Image Credit:AdobeStock) A study of the ocular features of Sjogren’s disease reported the heterogeneity of the disorder’s ocular presentations.1 The authors, led by research fellow Drew C. Baeza, MD, and associates, reported “distinct associations between specific dry eye and the…
Intravitreal complement inhibitor treatment for GA viewed favorably by patients | Ophthalmology Times
(Image Credit: AdobeStock) A new British study reported that treatment with intravitreal complement inhibitors (IVCIs) for geographic atrophy (GA) was viewed favorably by patients if the treatment was thought to impart visual benefits,1 according to first author Christiana Dinah, BSc,…